KVUE (Kenvue Inc.): Themes, ETFs, and Basket Ideas
Last updated June 2026
Short answer
What does Kenvue Inc. do?
Kenvue is the world's largest pure-play consumer health company, spun off from Johnson & Johnson in 2023. It owns a portfolio of iconic over-the-counter and personal-care brands organized into three segments: Self Care (Tylenol, Motrin, Sudafed, Zyrtec, Benadryl, Nicorette, Imodium), Skin Health and Beauty (Neutrogena, Aveeno, OGX), and Essential Health (Listerine, Band-Aid, Johnson's baby products, Aveeno). Kenvue sells everyday, repeat-purchase health and hygiene products through pharmacies, mass retailers, grocery, and e-commerce in markets around the world. The business makes money by leveraging strong, trusted brands and broad retail distribution to command premium pricing over private label in non-discretionary categories like pain relief, allergy care, oral care, and wound care. Many of its products are recommended by doctors and pharmacists, which reinforces brand loyalty. As a recently independent company, Kenvue is still building out standalone operations and pursuing cost efficiencies, while navigating litigation it inherited from its J&J consumer heritage. Headquartered in Summit, New Jersey.
Where is Kenvue Inc. heading?
1. Portfolio of trusted, defensive brands.
Kenvue owns category-leading names like Tylenol, Listerine, Neutrogena, Band-Aid, and Aveeno, many recommended by doctors and pharmacists. These are everyday health and hygiene essentials with repeat purchase patterns, giving Kenvue durable demand and pricing power over private label across the economic cycle.
2. Standalone efficiency and margin upside.
As a newly independent company, Kenvue is establishing its own supply chain, marketing, and back-office functions and pursuing cost-savings and restructuring programs. Optimizing the portfolio, rationalizing the brand lineup, and capturing efficiencies that were diluted inside J&J are levers to expand margins over time.
3. Skin health and emerging-market growth.
Skin Health and Beauty (Neutrogena, Aveeno) and self-care categories have room to grow through premiumization, new formats, and rising penetration in developing markets. E-commerce and direct channels offer additional reach for higher-margin personal-care and dermatological products.
4. Dividend and income profile.
Kenvue pays a meaningful dividend, in line with its consumer-staples positioning, making it a candidate for income and defensive portfolios. The stable, recurring nature of OTC health spending supports the payout, and management has signaled a commitment to returning cash to shareholders.
Risks worth tracking: Kenvue carries significant litigation overhang inherited from its J&J heritage, including high-profile Tylenol and talc-related claims, which create legal and headline risk. As a young standalone company it is still proving it can execute independently and grow organically, and early results have shown uneven volume trends. Private-label competition pressures pricing in OTC and personal care, input-cost inflation hits margins, and heavy international exposure adds currency risk. Activist pressure and possible portfolio changes add uncertainty, and slow growth makes the stock sensitive to interest rates and consumer trade-down.
Earnings and valuation (approximate, early 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Kenvue Inc.'s investor relations page or your broker.
- Revenue (TTM): ~$15 billion
- Operating margin: ~18%
- Net income (TTM): ~$1.5 billion
- P/E (TTM): ~20x
- Dividend yield: ~4%
- Free cash flow: ~$2 billion annually
- Spin-off date: 2023 (separated from Johnson & Johnson)
Kenvue trades at a consumer-staples multiple, somewhat below larger, faster-growing peers, reflecting its strong brands offset by litigation overhang and an unproven standalone growth track record. The above-average dividend yield is a key anchor for income investors. The valuation embeds expectations of margin improvement and steadier organic growth as the company matures independently and resolves legal uncertainties.
KVUE's competitors
Over-the-counter and self care
Haleon (Advil, Panadol, Centrum), Procter & Gamble (Vicks, Pepto-Bismol), and Bayer (Aleve, Claritin) compete in pain relief, allergy, and digestive care. Private-label OTC products from major retailers compete heavily on price across these categories.
Skin health and beauty
Neutrogena and Aveeno compete with L'Oreal (CeraVe, La Roche-Posay), Beiersdorf (Nivea, Eucerin), and Unilever (Dove, Vaseline) in dermatological skin care and personal care, both in mass and dermatologist-recommended segments.
Oral and essential health
Listerine and Band-Aid compete with Colgate-Palmolive and Procter & Gamble (Crest, Oral-B) in oral care, and with private-label and 3M (Nexcare) in wound care and first aid.
Using KVUE in a Walnut basket
The most useful question to ask about a single stock is rarely “will it go up?”. It's “does this fit a thesis I actually believe in, and how do I size it alongside other stocks that fit the same thesis?” That's what Walnut is built for.
Open the AI assistant on Walnut and describe a thesis (for example: “the AI infrastructure buildout”, “dividend growth large-caps”, “global semiconductors”) where KVUE would naturally fit. The AI proposes 5 to 6 constituents with target weights, you review, and you can fund the basket through your broker once you're ready.
Build a basket around KVUE with Walnut
Use Kenvue Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is KVUE's ticker symbol?
+
KVUE, listed on the New York Stock Exchange. Officially Kenvue Inc., headquartered in Summit, New Jersey. It trades during US market hours and is available at every major US brokerage.
What does Kenvue do?
+
Kenvue is the world's largest pure-play consumer health company. It makes and sells over-the-counter medicines and personal-care products under brands like Tylenol, Listerine, Neutrogena, Aveeno, Band-Aid, Johnson's, Zyrtec, and Nicorette through pharmacies, retailers, and e-commerce worldwide.
Who are Kenvue's main competitors?
+
Haleon, Procter & Gamble, and Bayer compete in over-the-counter medicines; L'Oreal, Beiersdorf, and Unilever in skin care; and Colgate-Palmolive and P&G in oral care. Private-label store brands compete on price across most of Kenvue's categories.
Is Kenvue the same as Johnson & Johnson?
+
No, not anymore. Kenvue was Johnson & Johnson's consumer health division until J&J spun it off as a separate public company in 2023. J&J kept its pharmaceutical and medical-device businesses, while Kenvue took the consumer brands like Tylenol, Listerine, and Neutrogena.
When did Kenvue spin off from J&J?
+
Kenvue separated from Johnson & Johnson in 2023, first through an IPO of a minority stake and then a full split, becoming an independent, publicly traded consumer health company. It inherited J&J's consumer brands and some related litigation.
Does Kenvue pay a dividend?
+
Yes. Kenvue pays a dividend consistent with its consumer-staples profile, currently yielding around 4%, which is above the broad-market average. The recurring nature of OTC health and hygiene spending supports the payout, and management has emphasized returning cash to shareholders.
Is Kenvue a consumer staples stock?
+
Yes. Under GICS classification, Kenvue is in the Consumer Staples sector (personal products / consumer health). Its everyday health and hygiene products make it a defensive holding that tends to be steadier than discretionary names during downturns.
What litigation does Kenvue face?
+
Kenvue inherited legal exposure from its J&J consumer heritage, including high-profile claims related to Tylenol and talc-based products. These cases create ongoing legal costs and headline risk, and the outcomes are uncertain, which is a recurring factor weighing on the stock.
Which ETFs hold Kenvue?
+
KVUE appears in broad-market funds like VOO and VTI at small weights and holds a meaningful position in the consumer-staples fund XLP. Given its above-average yield, it can also appear in dividend-oriented funds when it screens favorably.
What is Kenvue's dividend yield?
+
Approximately 4% as of early 2026, above the broad-market average. The relatively high yield reflects Kenvue's defensive profile and the discount the market applies for litigation overhang and an unproven standalone growth record. The yield is a key anchor for income investors.
Which thematic baskets typically include Kenvue?
+
Two themes on Walnut. Dividend income, given the above-average yield, and Consumer staples / defensive, given the trusted OTC and personal-care portfolio. KVUE is used as a defensive income holding, with litigation risk as a noted caveat.
Is Kenvue a good stock to buy?
+
Descriptive, not a recommendation. Kenvue is a defensive consumer-health company with leading brands like Tylenol and Neutrogena and a roughly 4% yield, offset by litigation overhang from its J&J heritage, an unproven standalone growth record, and private-label competition. Whether it fits a portfolio depends on your goals, time horizon, and risk tolerance. Walnut is informational, not investment advice.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Kenvue Inc.'s investor relations page or your broker before making investment decisions.